Additive effects of medroxyprogesterone acetate and 5-fluorouracil derivative on 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors

Anti-Cancer Drugs

Volumn 9, Issue 4, 1998, Pages 351-357

  Sakamoto, Shinobu ^a   Hara, Yukichi ^a   Mitamura, Tadasu ^a   Sassa, Shuji ^a   Kudo, Hideki ^a   Suzuki, Satoe ^a   Kuwa, Katsuhiko ^a   Okayasu, Isao ^b   Shinoda, Hisashi ^c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; Gene expression; Medroxyprogesterone acetate; Rat mammary tumor; Thymidylate synthetase

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; BROXURIDINE; ESTRADIOL; FLUOROURACIL; FLUOROURACIL DERIVATIVE; MEDROXYPROGESTERONE ACETATE; MESSENGER RNA; PROGESTERONE; PROLACTIN; TEGAFUR; THYMIDINE KINASE; THYMIDYLATE SYNTHASE; UFT; URACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY GROWTH; BONE ATROPHY; BONE DENSITY; BONE MINERAL; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; NONHUMAN; ORAL DRUG ADMINISTRATION; ORGAN WEIGHT; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031747838     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199804000-00009     Document Type: Article

References (24)

1. Di Marco A. The antitumor activity of 6a-methyl-17a-acetoxy progesterone (MPA) in experimental mammary cancer. In: Role of medroxyprogesterone in endocrine-related tumors. New York: Raven Press 1980: 1-20.
2. Pannuti F, Martoni A, Pollutri E, et al. Medroxyprogesterone acetate (MPA): effects of massive doses in advanced breast cancer. IRCS Med Sci 1974; 2: 1605.
3. Tominaga T, Abe O, Oshima A, et al. Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer. Eur J Cancer 1994; 30A: 959-64.
4. Hupperets PSGJ, Wils J, Volovics L, et al. Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients. Ann Oncol 1993; 4: 295-301.
5. Bonsignori M, Rossi G, Sturba F, et al. MPA-Hematology Italian Cooperative Group. Protective effects of high-dose medroxy-progesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. Chemioterapia 1986; 5: 134-9.
6. Marunaka T, Umeno Y, Yoshida K, et al. High-pressure liquid chromatographic determination of ftorafur and GLC-mass spectrometric determination of 5-FU and uracil in biological materials after oral administration of uracil plus ftorafur. J Pharmac Sci 1980; 69: 209-13.
7. Sneider TW, Potter VR, Morris HP. Enzymes of thymidine triphosphate synthesis in selected Morris hepatomas. Cancer Res 1969; 29: 40-54.
8. Herzfeld A, Legg MA, Greengard O. Human colon tumors: enzymic and histological characteristics. Cancer 1978; 42: 1280-3.
9. Weber G, Kizaki H, Tzeng D, et al. Colon tumor: enzymology of the neoplastic program. Life Sci 1978; 23: 29-36.
10. Sakamoto S, Kuwa K, Tsukada K, et al. Relative activities of thymidylate synthetase and thymidine kinase in 1.2-dimethylhydrazine-induced colon carcinomas in rats. Carcinogenesis 1987; 8: 405-8.
11. Dunlap RB, Harding NGL, Huennekens FM. Thymidylate synthetase from amethopterin-resistant Lactobacillus casei. Biochemistry 1971; 10: 88-97.
12. Taylor AT, Stafford MA, Jones OW. Properties of thymidine kinase partially purified from human fetal and adult tissue. J Biol Chem 1972; 247: 1930-5.
13. O'Driscoll L, Kennedy S, McDermott E, et al. Multiple drug resistance-related messenger RNA expression in archival formalin-fixed paraffin-embedded human breast tumour tissue. EurJ Cancer 1996; 32A: 128-33.
14. Shoji K, Horiuchi H, Shinoda H. Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats. J Periodont Res 1995; 30: 277-84.
15. Pannuti F, Martoni A, Cilenti G, et al. Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients. Eur J Cancer Clin Oncol 1988; 24: 423-9.
16. Aldaz CM, Liao QY, LaBate M, et al. Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. Carcinogenesis 1996; 17: 2069-72.
17. Sakamoto S, Mori T, Shinoda H, et al. Effects of conjugated estrogens with or without medroxyprogesterone acetate on mammary carcinogenesis, uterine adenomyosis and femur in mice. Acta Anatom, in press.
18. Mizukami Y, Tajiri K, Nonomura A, et al. Effects of tamoxifen, medroxyprogesterone acetate and estradiol on tumor growth and oncogene expression in MCF-7 breast cancer cell line transplanted into nude mice. Anticancer Res 1991; 11: 1333-8.
19. Hackenberg R, Hawighorst T, Filmer A, et al. Medroxyprogesterone acetate inhibits the proliferation of estrogen- and progestrone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor. Breast Cancer Res Treat 1993; 25: 217-24.
20. Ishikawa H, Iino Y, Izuo M, et al. Effects of chemoendocrine therapy with medroxyprogesterone acetate (MPA) on growth of DMBA-induced rat mammary tumor. Jpn J Cancer Clin 1986; 32: 151-5.
21. Sola G, Castegnaro E, Lenaz GR, et al. Hormone interference in metastatic breast cancer patients treated with medroxyprogesterone acetate at massive doses: preliminary results. IRCS Med Sci 1978; 6: 129.
22. Muccioli G, Racca S, Ricci Gamalero S, et al. Effects of medroxyprogesterone acetate on serum prolactin levels and liver prolactin binding capacity in the rat. Pharmacol Res Commun 1988; 20: 719-30.
23. Isserow JA, Rucinski B, Romero DF, et al. The effect of medroxyprogesterone acetate on bone metabolism in the oophorectomized, tamoxifen-treated rat. Endocrinology 1995; 136: 713-9.
24. Barengolts EI, Gajardo HF, Rosol TJ, et al. Effects of progesterone on postovariectomy bone loss in aged rats. J Bone Miner Res 1990; 5: 1143-7.